Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | ACP3 | P15309 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1720817 | 0.84 | IDO1 (0.38) | MAPTIDO1MLYCDALDH1A1 | |
| SCHEMBL1720267 | 0.81 | TAAR1 (0.39) | TAAR1ADRB2ADRB1LMNAIDO1 | |
| SCHEMBL2260409 | 0.80 | TAAR1 (0.41) | TAAR1ADRB2ADRB1LMNAIDO1 | |
| SCHEMBL73993 | 0.77 | HTR2A (0.58) | HTR2AHTR2BHTR2CACP3TAAR1 | |
| SCHEMBL165251 | 0.77 | LMNA (0.59) | TAAR1LMNAOPRK1MEN1KMT2A | |
| SCHEMBL1720788 | 0.75 | PTPN7 (0.42) | EPHX1 | |
| SCHEMBL568256 | 0.74 | ADH1B (0.53) | HTR2AHTR2BHTR2CACP3TAAR1 | |
| SCHEMBL1720376 | 0.74 | HTR2A (0.54) | HTR2AHTR2BHTR2CACP3TAAR1 | |
| SCHEMBL19040917 | 0.74 | HTR2A (0.54) | HTR2AHTR2BHTR2CACP3TAAR1 | |
| SCHEMBL1720582 | 0.74 | HTR2A (0.59) | HTR2AHTR2BHTR2CACP3TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730126-B1 | NOVEL BENZOXAZINONE DERIVATIVES USED AS LONG-ACTING BETAMIMETICS FOR TREATING RESPIRATORY ILLNESSES | BOEHRINGER INGELHEIM INT (DE) | 2012-01-11 | — | — | EP | disclosed |
| US-7244728-B2 | Long acting betamimetics for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-17 | — | — | US | disclosed |
| EP-1730126-A1 | NOVEL BENZOXAZINONE DERIVATIVES USED AS LONG-ACTING BETAMIMETICS FOR TREATING RESPIRATORY ILLNESSES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005092870-A1 | NOVEL BENZOXAZINONE DERIVATIVES USED AS LONG-ACTING BETAMIMETICS FOR TREATING RESPIRATORY ILLNESSES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-06 | — | — | WO | disclosed |
| US-20050209227-A1 | Novel long acting betamimetics for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-22 | — | — | US | disclosed |
| EP-1577306-A1 | novel benzoxazinone derivatives as slow-acting betamimetics and use thereof in treatment of respiratory tract diseases | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209227-A1 | Novel long acting betamimetics for the treatment of respiratory diseases | ADRA1D, ADRB2, ADRA1A | HTR2A 157/4885HTR2B 328/4885HTR2C 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.